Recent clinical trials have shown that sodium glucose co-transport 2 (SGLT2) inhibitors have
dramatic beneficial cardiovascular outcomes. These include a reduced incidence of …

Sodium-glucose cotransporter 2 (SGLT2) inhibitors exert hypoglycemic and diuretic effects
by inhibiting the absorption of sodium and glucose from the proximal tubule. Currently …

Background Type 2 diabetes mellitus (T2DM) greatly increases the risks of cardiovascular
disease and heart failure. In particular, left ventricular diastolic dysfunction that develops …

Chronic diabetic complications are classified as microvascular or macrovascular and
contribute to mortality and loss of quality of life. Hyperglycemia plays a critical role in the …

The development of sodium-glucose transporter 2 inhibitor (SGLT2i) broadens the
therapeutic strategies in treating diabetes mellitus. By inhibiting sodium and glucose …

The EMPA-REG OUTCOME study revealed that a sodium-glucose cotransporter 2 (SGLT2)
inhibitor, empagliflozin, can remarkably reduce cardiovascular (CV) mortality and heart …

Background In patients with type 2 diabetes mellitus (T2DM) the vaso-vagal syncope (VVS)
recurrence could be due to the alteration of autonomic system function, evaluated by heart …

Abstract Sodium glucose cotransporter 2 (SGLT-2) inhibitors are the latest class of
antidiabetic medications. They prevent glucose reabsorption in the proximal convoluted …

Abstract Purpose of Review We sought to review currently available data on the safety and
efficacy of sodium-glucose cotransporter 2 (SGLT2) inhibitors in type 2 diabetes mellitus …

Type 2 diabetes mellitus and arterial hypertension are major cardiovascular risks factors
which shares metabolic and haemodynamic abnormalities as well as pathophysiological …